The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index; 9 of the 41 sources its claims cite were checked for support.
An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species
Open accessAbstract
Recombinant adeno-associated viruses (rAAVs) have emerged as promising gene therapy vectors due to their proven efficacy and safety in clinical applications. In non-human primates (NHPs), rAAVs are administered via suprachoroidal injection at a higher dose. However, high doses of rAAVs tend to increase additional safety risks. Here, we present a novel AAV capsid (AAVv128), which exhibits significantly enhanced transduction efficiency for photoreceptors and retinal pigment epithelial (RPE) cells, along with a broader distribution across the layers of retinal tissues in different animal models (mice, rabbits, and NHPs) following intraocular injection. Notably, the suprachoroidal delivery of AAVv128-anti-VEGF vector completely suppresses the Grade IV lesions in a laser-induced choroidal neovascularization (CNV) NHP model for neovascular age-related macular degeneration (nAMD). Furthermore, cryo-EM analysis at 2.1 Å resolution reveals that the critical residues of AAVv128 exhibit a more robust advantage in AAV binding, the nuclear uptake and endosome escaping. Collectively, our findings highlight the potential of AAVv128 as a next generation ocular gene therapy vector, particularly using the suprachoroidal delivery route.
Overview
CoChat Summary
TL;DR
AAVv128, an AAV8-derived capsid engineered by rational design, shows enhanced retinal transduction across mice, rabbits, and non-human primates and suppresses Grade IV lesions in a laser-induced CNV NHP model when delivering anti-VEGF via suprachoroidal injection. Cryo-EM at 2.1 Å links its VP3 VIII loop changes to improved binding, cellular uptake, and nuclear entry.
Key findings
- After intravitreal injection in mice, AAVv128 produced the highest eGFP mRNA among tested variants, 75-fold higher than AAV8 (6 × 10⁸ vg/eye, n = 3).
- After subretinal injection in mice, AAVv128 showed 2-fold higher mean pixel intensity per area at Day 14 and 1.4-fold at Day 28, and 3.7-fold higher total pixel intensity at Day 14 and 3.2-fold at Day 28 versus AAV8; vector genome copies were 3.7-fold higher and relative eGFP copies/cell 3.9-fold higher.
- In rabbits, AAVv128 vector genome abundance was 12.4-fold higher than AAV8 after intravitreal injection and 23.2-fold higher after suprachoroidal injection. In NHP suprachoroidal delivery, AAVv128 increased eGFP fluorescence in peripheral fundus.
- In the laser-induced CNV NHP model, AAVv128-anti-VEGF via suprachoroidal injection yielded 0% Grade IV lesions at 35 and 49 days, versus 43.75% and 70.83% for vehicle and 31.25% and 41.67% for AAV8; retinal anti-VEGF levels were 2112 ng/g (OS) and 4056 ng/g (OD) for AAVv128 versus 39.12 ng/g and 52.8 ng/g for AAV8.
- AAVv128 had pI 7.6930 versus AAV8 6.8590, infectivity 75.0 ± 37.5 vg/IU versus 797.7 ± 165.1 vg/IU, and a 2.1 Å cryo-EM structure showing a more positively charged VP3 VIII loop with additional hydrogen-bond interactions.
Methods
- Rational design used AAV8 capsid as scaffold, replacing Q588–A592 or N263–T274 in VP3 VIII or VP3 VI variable regions with 18 peptides of 5–14 amino acids; vectors packaged eGFP, mCherry, or anti-VEGF cassettes flanked by AAV2 ITRs and were produced by HEK293T triple transfection.
- Animal testing used C57BL/6J mice, New Zealand White rabbits, and cynomolgus monkeys; routes included intravitreal, subretinal, and suprachoroidal injection, with a laser-induced CNV NHP model for nAMD efficacy.
- Main analyses included qRT-PCR/qPCR, ELISA, OCT/fundoscopy/FFA/SLO, immunofluorescence, DSF, cIEF, TCID50/qPCR infectivity, neutralizing antibody assays, AAV binding/uptake/nuclear fractionation assays, cryo-EM at 2.1 Å, and two-sided t-tests or one-way ANOVA.
Limitations
- Stated limitations: Not stated in the paper.
- Evident from the text: NHP anti-VEGF expression in Fig. 8a used n = 1 per group, while FFA efficacy used n = 8; some NHP transduction imaging also used n = 1.
- Evident from the text: no human data are reported, so clinical translatability remains untested; the cryo-EM map resolved only residues 218–743, with VP1u and VP2 domains unresolved.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
4 Valid · 1 Not valid · 22 Not checked · 101 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“It has been reported that a higher rAAV dose leads to a higher incidence of intraocular inflammation29.”
§ An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species > Introduction
What the sources say
- Disputedcites [29] Bouquet, C. et al. Immune response and intraocular inflammation in patients with leber hereditary optic neuropathy treated with intravitreal injection of recombinant adeno-associated virus 2 carrying the ND4 gene: a secondary analysis of a phase 1/2 clinical trial. JAMA Ophthalmol. 137, 399–406 (2019). sourceExperimental — accuracy not yet measured
The Discussion states that ocular inflammation could not be predicted from the viral dose administered, contrary to the claimed increase in incidence at higher doses. The Assessment of Ocular Inflammation section also reports inflammation across dose levels, without finding a dose association for its intensity. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“In a study, it was observed that the administration of a lower dose of AAV8 (7×1011 vg/eye, rhesus 01) did not result in any detectable expression at any time points.”
§ An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species > Discussion
What the sources say
- Supportedcites [33] Yiu, G. et al. Suprachoroidal and Subretinal Injections of AAV Using Transscleral Microneedles for Retinal Gene Delivery in Nonhuman Primates. Mol. Ther. Methods Clin. Dev. 16, 179–191 (2020). source
The “Suprachoroidal AAV8 Transduction Is Diffuse, Peripheral, and Circumferential” section (p. 3) identifies rhesus 01 as receiving the lower AAV8 dose of 7×10¹¹ vg/eye and states that it showed no detectable expression at any time point. (LLM, conf=0.94)
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In fact, the transduction efficiency of AAV8 in photoreceptors and RPE was found to be superior to that of AAV260.”
§ An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species > Discussion
What the sources say
- Supportedcites [60] Vandenberghe, L. H. et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci. Transl. Med. 3, 88ra54 (2011). source
The Results section 'Quantitative assessment of transduction' states that at the 10^10 genome copy dose AAV2 and AAV8 target 30% and 70%, respectively, of RPE and photoreceptor cells, and that AAV8 consistently gave higher GFP expression than AAV2 at that dose, with AAV2 needing a 10-fold higher dose to match it. The Results 'Retinal cell tropism and AAV serotype' passage (p. preceding Fig. 2 discussion) states directly that both serotypes transduce RPE efficiently at low doses while 'At higher doses, AAV8 is more efficient than AAV2 at transducing photoreceptor cells,' and the DISCUSSION adds that AAV8 RPE transduction at 10^9 gc equals AAV2 at a 10-fold higher dose. The only qualifier the citing sentence drops is that AAV2 can reach comparable levels at ~10-fold higher dose, which does not contradict superiority at matched dose. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Notably, AAVv128 demonstrated the highest mRNA expression, with a level that was 75-fold higher than that of AAV8 (Supplementary Table 3).”
§ An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species > Results > Rational engineering and screening of AAV8-based capsid variants
boostedstates an associationn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“NHPs eyes treated by suprachoroidal injection of the AAV8 and AAVv128 capsid confers detectable eGFP expression at days 14 post-injection (3.5×1012 vg/eye, 100 μL volume, n = 1).”
§ An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species > Results > AAVv128 outperforms AAV8 in intravitreal and suprachoroidal gene deliveries to rabbits and suprachoroidal gene delivery to NHPs
plainstates a causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
56 more claims
Create a free account to see all 128 claims and to verify the 32 references still open.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 45
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AAVv128 exhibits an enhanced rate and area of transduction of the RPE and retina across several routes of vector delivery (subretinal, intravitreal and suprachoroidal) and animal models.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Luo et al., 2024
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species > Methods > The thermal stability of rAAV vector was determined by differential scanning fluorimetry (DSF) analysis using Uncle
“rAAV samples (titer: 5×1012 vg/mL) were adjusted to different pH levels ranging from pH 7 to pH 4.”
§ An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species > Results > The thermal stability of AAVv128 is comparable to AAV8 and shows stronger cell transduction in vitro
“At pH 8.0, AAVv128 demonstrated peak signals at approximately 56.8 °C, while the peak DNA accessibility for AAV8 occurred at around 58.2 °C (Fig. 4a).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species > Results > Suprachoroidal injection of AAVv128 vector can prevent nAMD by Laser-induced CNV and produces more robust transduction and inhibition of VEGF in NHP retinal tissues
“at 35-days and 49-days (14-days and 28-days post Laser-induced CNV model)”
§ An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species > Results > Suprachoroidal injection of AAVv128 vector can prevent nAMD by Laser-induced CNV and produces more robust transduction and inhibition of VEGF in NHP retinal tissues
“AAVv128-anti-VEGF vector was injected into suprachoroidal space at Day 0, and six laser spots were applied around the macula of each eye using laser at 28-days”
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination
Punjani, A., Rubinstein, J. L., Fleet, D. J., & Brubaker, M. A. (2017) · Nature Methods · doi:10.1038/nmeth.4169 · Cited by 11,626
UCSF ChimeraX: Meeting modern challenges in visualization and analysis
Goddard, T. D., Huang, C. C., Meng, E. C., Pettersen, E. F., Couch, G. S., Morris, J. H., & Ferrin, T. E. (2018) · Protein Science · doi:10.1002/pro.3235 · Cited by 5,267
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Age-related macular degeneration
Mitchell, P., Liew, G., Gopinath, B., & Wong, T. Y. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31550-2 · Cited by 1,511
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Cited by
Wang, J.-H., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.017 · Cited by 53
Adeno-associated virus therapies: Pioneering solutions for human genetic diseases
Liu, D., Tian, L., Liu, L., Che, X., Li, X., Liu, C., & Wu, G. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.09.003 · Cited by 32
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“AAVv128 is an additional capsid variant, discovered by rational design (Luo et al., 2024).”
What’s New in Ocular Drug Delivery: Advances in Suprachoroidal Injection since 2023
Wu, K. Y., Gao, A., Giunta, M., & Tran, S. D. (2024) · Pharmaceuticals · doi:10.3390/ph17081007 · Cited by 30
“However, non-viral gene therapies can result in variable expression and have variable risks of immunogenic responses.”
BackgroundCorydon, T. J., & Bek, T. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101323 · Cited by 20
Metadata
- Authors
- Luo, S., Jiang, H., Li, Q., Qin, Y., Yang, S., Li, J., Xu, L., Gou, Y., Zhang, Y., Liu, F., Ke, X., Zheng, Q., & Sun, X.
- Affiliations
- Sichuan University (CN)
- Guangzhou Laboratory (CN)
- Corresponding author
- Ke, Xiao
- Zheng, Qiang
- Sun, Xun
- ORCID
- Venue
- Nature Communications
- Published
- 2024-05-06
- Volume
- 15
- Issue
- 1
- Pages
- 3780-3780
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC11074261
- OpenAlex
- W4396673495
- Semantic Scholar
- 8064e5b2b777e0cc8c156f7b4a02b55831bae6ca
- Cited by
- 39
- References
- 93
- Citations by year
- 2026: 11 · 2025: 18 · 2024: 10
- FWCI
- 10.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- the Fundamental Research Funds for the Central Universities
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, ocular gene delivery, suprachoroidal injection, retinal transduction, photoreceptors, retinal pigment epithelium, choroidal neovascularization, neovascular age-related macular degeneration, anti-VEGF therapy, non-human primates, cryo-EM structure, endosomal escape, nuclear uptake, retinal gene therapy
- MeSH terms
- Dependovirus, Animals, Disease Models, Animal, Genetic Vectors, Humans, Macular Degeneration, Male, Mice, Inbred C57BL, Rabbits, Retina, Transduction, Genetic, Genetic Therapy, Gene Transfer Techniques, Choroidal Neovascularization, Capsid Proteins, Vascular Endothelial Growth Factor A, Mice, Retinal Pigment Epithelium, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species. https://app.cochat.ai/papers/10.1038/s41467-024-48221-4
- The paper
- Luo, S., Jiang, H., Li, Q., Qin, Y., Yang, S., Li, J., Xu, L., Gou, Y., Zhang, Y., Liu, F., Ke, X., Zheng, Q., & Sun, X. (2024). An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species. Nature Communications. https://doi.org/10.1038/s41467-024-48221-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.